Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m besilesomab

Drug Profile

Tc 99m besilesomab

Alternative Names: 99Tcm-BW250-183; BW 250 183; Scintimun; Tc 99m-labeled monoclonal antibody BW 250/183; Technetium-99m-antigranulocyte antibody BW 250-183

Latest Information Update: 12 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CIS bio international
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases; Infections; Inflammation; Osteomyelitis

Most Recent Events

  • 12 Jun 2015 Launched for Osteomyelitis (Diagnosis) in Austria, Belgium, Croatia, Finland, Germany, Latvia, Italy, Lithuania, Malta, Slovenia and Slovakia (IV) before June 2015
  • 23 Oct 2009 The Committee for Medicinal Products for Human Use recommends approval of Tc 99m besilesomab for Osteomyelitis diagnosis in the EU
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top